Data on compounded GLP1 medications is extremely limited, as they are not typically run through insurance, nor are they assigned a National Drug Code (NDC), which is used to track usage of FDA approved therapeutics
For most individuals, oral dosage forms offer a more convenient formulation compared to injections, especially for those who may not be comfortable with needles
Retatrutide and cagrilintide, which cannot be used in compounding under federal law
Tirzepatide , a medication garnering significant attention in recent times, presents a fresh perspective on addressing weight issues with its innovative approach
Leptin Resistance The leptin receptor genetic variants that are tied to increased weight may also exacerbate leptin resistance
Some individuals benefit from titration to higher maintenance doses